Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Int Rep
Autors principals: Hanset, Nicolas, Esteve, Emmanuel, Plaisier, Emmanuelle, Johanet, Catherine, Michel, Pierre-Antoine, Boffa, Jean-Jacques, Fievet, Patrick, Mesnard, Laurent, Morelle, Johann, Ronco, Pierre, Dahan, Karine
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056852/
https://ncbi.nlm.nih.gov/pubmed/32154454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2019.12.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars